| Type of Material: | Thesis |
| Title: | Formulation Design For Improvement Of Performance Characteristics Of BCS IV Drug |
| Researcher: | Dahiya, Sandeepkumar |
| Guide: | Savjani, Jignasa |
| Department: | Institute of Pharmacy |
| Publisher: | Nirma University, Ahmedabad |
| Place: | Ahmedabad |
| Year: | 2023 |
| Language: | English |
| Subject: | BCS-IV Drug | Clinical Pre Clinical and Health | Formulation Design | Pharmacology and Pharmacy | Pharmacology and Toxicology | Pharmacy | Medical Sciences | Medical and Health Sciences |
| Dissertation/Thesis Note: | PhD; Institute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad; 2023 |
| Fulltext: | Shodhganga |
| 000 | 00000ntm a2200000ua 4500 | |
| 001 | 456629 | |
| 003 | IN-AhILN | |
| 005 | 2024-10-11 15:58:05 | |
| 008 | __ | 241011t2023||||ii#||||g|m||||||||||eng|| |
| 035 | __ | |a(IN-AhILN)th_456629 |
| 040 | __ | |aNIRU_382481|dIN-AhILN |
| 041 | __ | |aeng |
| 100 | __ | |aDahiya, Sandeepkumar|eResearcher |
| 110 | __ | |aInstitute of Pharmacy|bNirma University, Ahmedabad|dAhmedabad|ein|0U-0146 |
| 245 | __ | |aFormulation Design For Improvement Of Performance Characteristics Of BCS IV Drug |
| 260 | __ | |aAhmedabad|bNirma University, Ahmedabad|c2023 |
| 300 | __ | |dDVD |
| 502 | __ | |cInstitute of Pharmacy, Nirma University, Ahmedabad, Ahmedabad|d2023|bPhD |
| 518 | __ | |d2023|oDate of Award |
| 518 | __ | |oDate of Registration|d2016 |
| 520 | __ | |aAbiraterone acetate has very low bioavailability and drastic food effect to warrant a dosing regimen under fasting state only. Therefore, we aimed to develop and optimize a liquisolid compact formulation of abiraterone acetate to improve biopharmaceutical attributes aided by pharmacokinetic modelling and achieve dose reduction with no food effect on the formulation. Preliminary studies highlighted the importance of the selection of olive oil as a compatible vehicle. The pharmacokinetic model, integrated with gastrointestinal physiology, was used to predict fasted and fed state pharmacokinetic parameters. Optimization of the liquisolid formulation containing abiraterone acetate was carried at more than five times lower dose, i.e. 190 mg, compared to 1,000 mg. A central composite design (CCD) was used to identify optimal levels of formulation factors, namely the amount of vehicle (olive oil), the amount of coating agent (silicon dioxide), and the amount of surfactant (polysorbate 80). Graphical optimization u |
| 650 | __ | |aPharmacy|2UGC |
| 650 | __ | |aMedical Sciences|2UGC |
| 650 | __ | |aMedical and Health Sciences|2AIU |
| 653 | __ | |aBCS-IV Drug |
| 653 | __ | |aClinical Pre Clinical and Health |
| 653 | __ | |aFormulation Design |
| 653 | __ | |aPharmacology and Pharmacy |
| 653 | __ | |aPharmacology and Toxicology |
| 700 | __ | |eGuide|aSavjani, Jignasa |
| 856 | __ | |uhttp://shodhganga.inflibnet.ac.in/handle/10603/509892|yShodhganga |
| 905 | __ | |afromsg |
User Feedback Comes Under This section.